3 hours Why Pfizer Will Find It Hard to Appease Its Activist Investor The Wall Street Journal
The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.
The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.